Aristotle Funds, an investment advisor, released its “Growth Equity Fund” fourth-quarter 2025 investor letter. A copy of the letter can be downloaded here. U.S. equity markets reached new all-time ...

DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...

In February 2026, DexCom reported fourth-quarter 2025 sales of US$1,259.6 million and full-year 2025 sales of US$4,662 million, with net income rising to US$267.3 million for the quarter and US$836.3 ...

Tandem Diabetes Care, Inc. delivered strong Q4 '25 results, with revenue and gross margin beats driving a 32% stock surge.

Dexcom (Nasdaq:DXCM) announced that it appointed Rick Osterloh to its board of directors, effective Feb. 26, 2026.

Medtronic's diabetes spin-off MiniMed seeks $784M IPO at $7.86B valuation after six quarters of double-digit growth in booming CGM market.

Abbott (NYSE: ABT) today the FDA approved its CardioMEMS Hero next-generation pulmonary artery (PA) pressure reader.

Medtronic on Tuesday priced a planned initial public offering for its MiniMed diabetes spinoff at up to $784 million. MiniMed ...

For decades, a blood draw in a clinical lab was the only way to quantify your hormones. In 2026, that paradigm is shifting and we are seeing saliva cartridges analyzed by smartphone AI, DNA-based ...

Ultra-low-power TMR switches enable reliable CGM activation by minimizing energy consumption while maintaining accurate, responsive device performance.

Early clinical trials established the safety and feasibility of closed-loop insulin delivery, but the 2019 iDCL trial1 marked the first large, outpatient, randomised, controlled trial to show a ...

Market Overview and Growth OutlookThe global mHealth monitoring and diagnostic medical devices market is poised for strong ...